📑 Extensive Product Profile: Understanding Abiralieva 250mg Tablet 1. Clinical Indications & Usage Metastatic Castration-Resistant Prostate Cancer (mCRPC): Indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who have either received prior chemotherapy containing docetaxel or are chemotherapy-naive. Metastatic High-Risk Castration-Sensitive Prostate Cancer (mHSPC): Indicated in combination with prednisone/prednisolone and androgen deprivation therapy (ADT) for patients presenting with newly diagnosed high-risk metastatic hormone-sensitive prostate malignancy. Selective CYP17 Enzyme Inhibition: Abiraterone acetate is converted in vivo to abiraterone, a potent inhibitor of the CYP17 enzyme complex (17α-hydroxylase/C17,20-lyase). This enzyme complex is highly expressed in testicular, adrenal, and prostatic tumor tissues. Tri-Source Androgen Suppression: By blocking CYP17, Abiralieva halts the conversion of pregnenolone and progesterone into testosterone precursors. This completely disrupts androgen biosynthesis at all three biological sources: the testes, the adrenal glands, and within the tumor microenvironment itself. 3. Administration and Dosing Guide Administration Route: Abiralieva 250mg is an oral tablet formulation. It must be swallowed whole with water and should never be chewed, crushed, dissolved, or split. Strict Food Interactions (Empty Stomach Requirement): Abiralieva must be taken on an empty stomach. No food should be consumed for at least 2 hours before taking the dose, and no food should be consumed for at least 1 hour after taking the dose. Taking the medication with food significantly increases systemic exposure and can lead to toxicities. Standard Schedule: The typical recommended adult dosage is 1,000 mg (four 250 mg tablets) taken orally once daily, always in combination with a low-dose corticosteroid (such as Prednisone 5 mg twice daily or as instructed by the specialist). Dose titrations or temporary interruptions may be managed by the treating oncologist based on hepatic tolerance and toxicities. ⚠️ Safety, Side Effects, and Monitoring Mineralocorticoid Excess: Due to CYP17 inhibition, compensatory increases in adrenocorticotropic hormone (ACTH) can cause mineralocorticoid excess. This can manifest as severe hypertension, hypokalemia (low potassium), and fluid retention (edema). Blood pressure and potassium levels must be monitored closely at baseline and monthly. Hepatotoxicity: Significant elevations in serum transaminases (ALT and AST) and bilirubin have been reported. Liver Function Tests (LFTs) are mandatory prior to initiating therapy, every 2 weeks for the first 3 months of treatment, and monthly thereafter. Common Side Effects: Joint swelling or pain (arthralgia), muscle discomfort, hot flashes, diarrhea, urinary tract infections, cough, and changes in blood lipid profiles. 📦 Storage and Handling Specifications Storage Framework: Store Abiralieva 250mg tablets consistently below 20°C to 25°C (68°F to 77°F) in a dry, dark, climate-controlled warehouse corridor. Environmental Safeguards: Keep the tablets sealed tightly inside their original manufacturer protective container. Protect the bottles from high humidity, excess moisture, and direct UV light exposure. Keep strictly out of reach of children and domestic pets. 📄 Regulatory and Compliance Documentation Authentic Certificate of Analysis (COA) GMP compliant manufacturing credentials. Verified Batch Origin Ledger and commercial export documentation. 💡 Why Choose PRIMECARE IMPEX? Full Traceability Regulatory Alignment Secure Bulk Supply 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [GROUP OF PRIME CARE IMPEX PVT. LTD.] Your Trusted Pharmaceutical Exporter, Bulk Supplier, and Global Distributor from India. 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130
